{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:45:18Z","timestamp":1792086318207,"version":"4.4.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09860-5","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:02:10Z","timestamp":1792083730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of immune checkpoint\u2013related polymorphisms in PD-1, PD-L1, and CTLA-4 genes with susceptibility to genitourinary cancer: a meta-analysis"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-9365","authenticated-orcid":false,"given":"Chih-Heng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Wei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Hung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"1","key":"9860_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"9860_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semcancer.2018.04.008","volume":"55","author":"MH Wang","year":"2019","unstructured":"Wang MH, Cordell HJ, Van Steen K. Statistical methods for genome-wide association studies. Semin Cancer Biol. 2019;55:53\u201360. https:\/\/doi.org\/10.1016\/j.semcancer.2018.04.008.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"9860_CR3","doi-asserted-by":"publisher","first-page":"9940","DOI":"10.3390\/curroncol30110722","volume":"30","author":"PF Liao","year":"2023","unstructured":"Liao PF, Wang PY, Peng TR. Efficacy and safety of programmed death-1\/programmed death-ligand 1 inhibitor for metastatic urothelial carcinoma: A systematic review and meta-analysis. Curr Oncol. 2023;30(11):9940\u201352. https:\/\/doi.org\/10.3390\/curroncol30110722.","journal-title":"Curr Oncol"},{"issue":"11","key":"9860_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol"},{"issue":"7637","key":"9860_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349.","journal-title":"Nature"},{"key":"9860_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in cancer: Mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86. https:\/\/doi.org\/10.3389\/fonc.2018.00086.","journal-title":"Front Oncol"},{"issue":"6","key":"9860_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00439-013-1275-6","volume":"132","author":"W Wang","year":"2013","unstructured":"Wang W, Li F, Mao Y, Zhou H, Sun J, Li R, et al. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet. 2013;132(6):641\u20138. https:\/\/doi.org\/10.1007\/s00439-013-1275-6.","journal-title":"Hum Genet"},{"issue":"2","key":"9860_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00251-017-1015-5","volume":"70","author":"A Salmaninejad","year":"2018","unstructured":"Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, et al. PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics. 2018;70(2):73\u201386. https:\/\/doi.org\/10.1007\/s00251-017-1015-5.","journal-title":"Immunogenetics"},{"issue":"17","key":"9860_CR9","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1158\/0008-5472.Can-08-0806","volume":"68","author":"T Sun","year":"2008","unstructured":"Sun T, Zhou Y, Yang M, Hu Z, Tan W, Han X, et al. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res. 2008;68(17):7025\u201334. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-0806.","journal-title":"Cancer Res"},{"key":"9860_CR10","doi-asserted-by":"publisher","first-page":"1123832","DOI":"10.3389\/fimmu.2023.1123832","volume":"14","author":"DP Chen","year":"2023","unstructured":"Chen DP, Wen YH, Lin WT, Hsu FP, Yu KH. Exploration of the association between the single-nucleotide polymorphism of co-stimulatory system and rheumatoid arthritis. Front Immunol. 2023;14:1123832. https:\/\/doi.org\/10.3389\/fimmu.2023.1123832.","journal-title":"Front Immunol"},{"issue":"7","key":"9860_CR11","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.18632\/aging.205689","volume":"16","author":"M Yang","year":"2024","unstructured":"Yang M, Liu Y, Zheng S, Geng P, He T, Lu L, et al. Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies. Aging. 2024;16(7):6068\u201397. https:\/\/doi.org\/10.18632\/aging.205689.","journal-title":"Aging"},{"issue":"12","key":"9860_CR12","doi-asserted-by":"publisher","first-page":"e23164","DOI":"10.1016\/j.heliyon.2023.e23164","volume":"9","author":"H Pan","year":"2023","unstructured":"Pan H, Shi Z, Gao L, Zhang L, Wei S, Chen Y, et al. Impact of the cytotoxic T-lymphocyte associated antigen-4 rs231775 A\/G polymorphism on cancer risk. Heliyon. 2023;9(12):e23164. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23164.","journal-title":"Heliyon"},{"issue":"7","key":"9860_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/08916934.2021.1946796","volume":"54","author":"M Kawabata","year":"2021","unstructured":"Kawabata M, Inoue N, Watanabe M, Kobayashi A, Hidaka Y, Miyauchi A, et al. PD-1 gene polymorphisms and thyroid expression of PD-1 ligands differ between Graves\u2019 and Hashimoto\u2019s diseases. Autoimmunity. 2021;54(7):450\u20139. https:\/\/doi.org\/10.1080\/08916934.2021.1946796.","journal-title":"Autoimmunity"},{"key":"9860_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"9860_CR15","doi-asserted-by":"publisher","unstructured":"Wagner M, Tupikowski K, Jasek M, Tomkiewicz A, Witkowicz A, Ptaszkowski K, et al. SNP-SNP interaction in genes encoding PD-1\/PD-L1 axis as a potential risk factor for clear cell renal cell carcinoma. Cancers (Basel). 2020;12(12). https:\/\/doi.org\/10.3390\/cancers12123521.","DOI":"10.3390\/cancers12123521"},{"issue":"5","key":"9860_CR16","first-page":"334","volume":"10","author":"GVB Gomez","year":"2022","unstructured":"Gomez GVB, Longhi LNA, Saito HPA, Louren\u00e7o GJ, Dos Reis RB, Tobias Machado M, et al. PD1.5 variant on PDCD1 gene, regulator of T lymphocyte activity, influences non-muscle-invasive bladder cancer risk. Am J Clin Exp Urol. 2022;10(5):334\u201340.","journal-title":"Am J Clin Exp Urol"},{"issue":"11","key":"9860_CR17","doi-asserted-by":"publisher","first-page":"e48120","DOI":"10.7759\/cureus.48120","volume":"15","author":"STM Hlaing","year":"2023","unstructured":"Hlaing STM, Damayanti P, Zin Aung K, Tsukino H, Hinoura T, Kuroda Y. The Relationship Between PD-1(rs2227981) and PD-L1(rs2890658) Polymorphisms and Urothelial Cell Carcinoma. Cureus. 2023;15(11):e48120. https:\/\/doi.org\/10.7759\/cureus.48120.","journal-title":"Cureus"},{"issue":"2","key":"9860_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.56434\/j.arch.esp.urol.20267902.28","volume":"79","author":"K Kayar","year":"2026","unstructured":"Kayar K, Verim L, Sonmez D, Kadihasanoglu M, Demirkol S, Kucukhuseyin O, et al. Distribution of PD-1.5 gene variant (rs2227981): A possible approach for risk assessment in bladder cancer. Arch Esp Urol. 2026;79(2):233\u201340. https:\/\/doi.org\/10.56434\/j.arch.esp.urol.20267902.28.","journal-title":"Arch Esp Urol"},{"issue":"9","key":"9860_CR19","first-page":"821","volume":"31","author":"X Li","year":"2016","unstructured":"Li X, Liu J, Yu L, Shao S, Yu Q, Niu H, et al. Relationship between B7-H1 miRNA binding site C\/G single necleotiede polymorphism and the expression of B7-H1 protein in bladder transitional cell carcinoma. J Clin Urol (China). 2016;31(9):821\u20134.","journal-title":"J Clin Urol (China)"},{"issue":"7","key":"9860_CR20","first-page":"762","volume":"24","author":"J Liu","year":"2017","unstructured":"Liu J, Wang Y, Yu L, Niu H, Liu Y, Sun L. Research on clinicopathological relationship of SNP of PD-L1 gene 3\u2019UTR with BUC by case-control studies. Chin J Cancer Biother. 2017;24(7):762\u20136.","journal-title":"Chin J Cancer Biother"},{"issue":"2","key":"9860_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s12291-020-00881-x","volume":"36","author":"A Verma","year":"2021","unstructured":"Verma A, Mittal RD. Association of miRNA 30c, miRNA 181a and miRNA 570 SNPs with bladder cancer risk in North Indian population: A pilot study. Indian J Clin Biochem. 2021;36(2):194\u20139. https:\/\/doi.org\/10.1007\/s12291-020-00881-x.","journal-title":"Indian J Clin Biochem"},{"issue":"8","key":"9860_CR22","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.humimm.2007.05.002","volume":"68","author":"JM Cozar","year":"2007","unstructured":"Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol. 2007;68(8):698\u2013704. https:\/\/doi.org\/10.1016\/j.humimm.2007.05.002.","journal-title":"Hum Immunol"},{"issue":"2","key":"9860_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s11033-013-2919-2","volume":"41","author":"PK Jaiswal","year":"2014","unstructured":"Jaiswal PK, Singh V, Mittal RD. Cytotoxic T lymphocyte antigen 4 (CTLA4) gene polymorphism with bladder cancer risk in North Indian population. Mol Biol Rep. 2014;41(2):799\u2013807. https:\/\/doi.org\/10.1007\/s11033-013-2919-2.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"9860_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/tan.12671","volume":"86","author":"K Tupikowski","year":"2015","unstructured":"Tupikowski K, Partyka A, Kolodziej A, Dembowski J, Debinski P, Halon A, et al. CTLA-4 and CD28 genes\u2019 polymorphisms and renal cell carcinoma susceptibility in the Polish population\u2013a prospective study. Tissue Antigens. 2015;86(5):353\u201361. https:\/\/doi.org\/10.1111\/tan.12671.","journal-title":"Tissue Antigens"},{"issue":"4","key":"9860_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s12253-016-0180-4","volume":"23","author":"L Karabon","year":"2017","unstructured":"Karabon L, Tupikowski K, Tomkiewicz A, Partyka A, Pawlak-Adamska E, Wojciechowski A, et al. Is the genetic background of co-stimulatory CD28\/CTLA-4 pathway the risk factor for prostate cancer? Pathol Oncol Res. 2017;23(4):837\u201343. https:\/\/doi.org\/10.1007\/s12253-016-0180-4.","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"9860_CR26","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s13277-013-1152-x","volume":"35","author":"L Wang","year":"2014","unstructured":"Wang L, Su G, Zhao X, Cai Y, Cai X, Zhang J, et al. Association between the cytotoxic T-lymphocyte antigen 4\u2009+\u200949A\/G polymorphism and bladder cancer risk. Tumour Biol. 2014;35(2):1139\u201342. https:\/\/doi.org\/10.1007\/s13277-013-1152-x.","journal-title":"Tumour Biol"},{"key":"9860_CR27","doi-asserted-by":"publisher","first-page":"8143158","DOI":"10.1155\/2020\/8143158","volume":"2020","author":"F Mao","year":"2020","unstructured":"Mao F, Niu XB, Gu S, Ji L, Wei BJ, Wang HB. CTLA-4\u2009+\u200949A\/G polymorphism increases the susceptibility to bladder cancer in Chinese Han participants: A case-control study. Dis Markers. 2020;2020:8143158. https:\/\/doi.org\/10.1155\/2020\/8143158.","journal-title":"Dis Markers"},{"issue":"11","key":"9860_CR28","doi-asserted-by":"publisher","first-page":"e3741","DOI":"10.1016\/j.urolonc.2024.05.017","volume":"42","author":"A Koike","year":"2024","unstructured":"Koike A, Colado Sim\u00e3o AN, Ahrens TM, Cardoso KM, Espinosa BR, Gualberto RHG, et al. CTLA4 genetic variants associated with urothelial bladder cancer susceptibility. Urol Oncol. 2024;42(11):e3741\u201310. https:\/\/doi.org\/10.1016\/j.urolonc.2024.05.017.","journal-title":"Urol Oncol"},{"issue":"8","key":"9860_CR29","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3760\/cma.j.cn511374-20240118-00053","volume":"41","author":"J Li","year":"2024","unstructured":"Li J, Zhang L, Xie H, Ge Y, Wang L. [Association of CTLA-4 gene polymorphisms with the genetic susceptibility and prognosis of patients with Bladder urothelial carcinoma]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2024;41(8):988\u201393. https:\/\/doi.org\/10.3760\/cma.j.cn511374-20240118-00053.","journal-title":"Zhonghua Yi Xue Yi Chuan Xue Za Zhi"},{"issue":"10","key":"9860_CR30","doi-asserted-by":"publisher","first-page":"e48068","DOI":"10.7759\/cureus.48068","volume":"15","author":"P Damayanti","year":"2023","unstructured":"Damayanti P, Hlaing STM, Zin Aung K, Tsukino H, Hinoura T, Kuroda Y. The relationship between CTLA-4 (-318 C\/T) polymorphism and urothelial cancer carcinogenesis in Japanese patients. Cureus. 2023;15(10):e48068. https:\/\/doi.org\/10.7759\/cureus.48068.","journal-title":"Cureus"},{"issue":"2","key":"9860_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.prp.2018.12.002","volume":"215","author":"J Zou","year":"2019","unstructured":"Zou J, Wu D, Li T, Wang X, Liu Y, Tan S. Association of PD-L1 gene rs4143815 C\u2009>\u2009G polymorphism and human cancer susceptibility: A systematic review and meta-analysis. Pathol Res Pract. 2019;215(2):229\u201334. https:\/\/doi.org\/10.1016\/j.prp.2018.12.002.","journal-title":"Pathol Res Pract"},{"key":"9860_CR32","doi-asserted-by":"publisher","first-page":"878507","DOI":"10.3389\/fonc.2022.878507","volume":"12","author":"H Wan","year":"2022","unstructured":"Wan H, Zhou H, Feng Y, Chen Y, Zhu L, Mi Y. Comprehensive analysis of 29,464 cancer cases and 35,858 controls to investigate the effect of the cytotoxic T-lymphocyte antigen 4 gene rs231775 A\/G polymorphism on cancer risk. Front Oncol. 2022;12:878507. https:\/\/doi.org\/10.3389\/fonc.2022.878507.","journal-title":"Front Oncol"},{"issue":"5","key":"9860_CR33","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/s0210-4806(09)74180-4","volume":"33","author":"P S\u00e1enz L\u00f3pez","year":"2009","unstructured":"S\u00e1enz L\u00f3pez P, V\u00e1zquez Alonso F, Romero JM, Carretero R, Tallada Bu\u00f1uel M, Ruiz Cabello F, et al. [Polymorphisms in inflammatory response genes in metastatic renal cancer]. Actas Urol Esp. 2009;33(5):474\u201381. https:\/\/doi.org\/10.1016\/s0210-4806(09)74180-4.","journal-title":"Actas Urol Esp"},{"issue":"1","key":"9860_CR34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1159\/000489953","volume":"47","author":"M Fang","year":"2018","unstructured":"Fang M, Huang W, Mo D, Zhao W, Huang R. Association of five snps in cytotoxic T-Lymphocyte antigen 4 and cancer susceptibility: Evidence from 67 studies. Cell Physiol Biochem. 2018;47(1):414\u201327. https:\/\/doi.org\/10.1159\/000489953.","journal-title":"Cell Physiol Biochem"},{"key":"9860_CR35","doi-asserted-by":"publisher","first-page":"606721","DOI":"10.3389\/fimmu.2020.606721","volume":"11","author":"M Wagner","year":"2020","unstructured":"Wagner M, Jasek M, Karabon L. Immune checkpoint molecules-inherited variations as markers for cancer risk. Front Immunol. 2020;11:606721. https:\/\/doi.org\/10.3389\/fimmu.2020.606721.","journal-title":"Front Immunol"},{"key":"9860_CR36","doi-asserted-by":"publisher","unstructured":"de With M, Hurkmans DP, Oomen-de Hoop E, Lalouti A, Bins S, El Bouazzaoui S, et al. Germline variation in PDCD1 Is associated with overall survival in patients with metastatic melanoma treated with Anti-PD-1 monotherapy. Cancers (Basel). 2021;13(6). https:\/\/doi.org\/10.3390\/cancers13061370.","DOI":"10.3390\/cancers13061370"},{"issue":"3","key":"9860_CR37","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/art.20040","volume":"50","author":"SC Lin","year":"2004","unstructured":"Lin SC, Yen JH, Tsai JJ, Tsai WC, Ou TT, Liu HW, et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum. 2004;50(3):770\u20135. https:\/\/doi.org\/10.1002\/art.20040.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"9860_CR38","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10549-011-1440-3","volume":"129","author":"Z Hua","year":"2011","unstructured":"Hua Z, Li D, Xiang G, Xu F, Jie G, Fu Z, et al. PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. Breast Cancer Res Treat. 2011;129(1):195\u2013201. https:\/\/doi.org\/10.1007\/s10549-011-1440-3.","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"9860_CR39","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1158\/0008-5472.Can-09-0176","volume":"69","author":"T Sun","year":"2009","unstructured":"Sun T, Hu Z, Shen H, Lin D. Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res. 2009;69(15):6011\u20134. https:\/\/doi.org\/10.1158\/0008-5472.Can-09-0176.","journal-title":"Cancer Res"},{"key":"9860_CR40","doi-asserted-by":"publisher","first-page":"1160368","DOI":"10.3389\/fmed.2023.1160368","volume":"10","author":"M Angulo-Aguado","year":"2023","unstructured":"Angulo-Aguado M, Orjuela-Amarillo S, Mora-J\u00e1come JF, C\u00f3rdoba LP, Gallego-Ortiz A, Gaviria-Sabogal CC, et al. Functional analysis of CTLA4 promoter variant and its possible implication in colorectal cancer immunotherapy. Front Med (Lausanne). 2023;10:1160368. https:\/\/doi.org\/10.3389\/fmed.2023.1160368.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"9860_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/jcma.0000000000000851","volume":"86","author":"HY Chang","year":"2023","unstructured":"Chang HY, Liu CY, Lo YL, Chiou SH, Lu KH, Lee MC, et al. Cytotoxic T-lymphocyte antigen 4 polymorphisms and breast cancer susceptibility: Evidence from a meta-analysis. J Chin Med Assoc. 2023;86(2):207\u201319. https:\/\/doi.org\/10.1097\/jcma.0000000000000851.","journal-title":"J Chin Med Assoc"},{"issue":"6939","key":"9860_CR42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature01621","volume":"423","author":"H Ueda","year":"2003","unstructured":"Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003;423(6939):506\u201311. https:\/\/doi.org\/10.1038\/nature01621.","journal-title":"Nature"},{"issue":"8","key":"9860_CR43","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1007\/s11033-013-2614-3","volume":"40","author":"DM Kordi-Tamandani","year":"2013","unstructured":"Kordi-Tamandani DM, Vaziri S, Dahmardeh N, Torkamanzehi A. Evaluation of polymorphism, hypermethylation and expression pattern of CTLA4 gene in a sample of Iranian patients with schizophrenia. Mol Biol Rep. 2013;40(8):5123\u20138. https:\/\/doi.org\/10.1007\/s11033-013-2614-3.","journal-title":"Mol Biol Rep"},{"issue":"5","key":"9860_CR44","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1530\/eje-09-0600","volume":"161","author":"J Daroszewski","year":"2009","unstructured":"Daroszewski J, Pawlak E, Karabon L, Frydecka I, Jonkisz A, Slowik M, et al. Soluble CTLA-4 receptor an immunological marker of Graves\u2019 disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur J Endocrinol. 2009;161(5):787\u201393. https:\/\/doi.org\/10.1530\/eje-09-0600.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"9860_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4174\/astr.2024.106.5.263","volume":"106","author":"T Jin","year":"2024","unstructured":"Jin T, Park KS, Nam SE, Lim SH, Kim JH, Noh WC, et al. CTLA4 expression profiles and their association with clinical outcomes of breast cancer: a systemic review. Ann Surg Treat Res. 2024;106(5):263\u201373. https:\/\/doi.org\/10.4174\/astr.2024.106.5.263.","journal-title":"Ann Surg Treat Res"},{"issue":"2","key":"9860_CR46","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.cllc.2016.09.010","volume":"18","author":"A Lafuente-Sanchis","year":"2017","unstructured":"Lafuente-Sanchis A, Z\u00fa\u00f1iga \u00c1, Estors M, Mart\u00ednez-Hern\u00e1ndez NJ, Cremades A, Cuenca M, et al. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017;18(2):e109\u201316. https:\/\/doi.org\/10.1016\/j.cllc.2016.09.010.","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"9860_CR47","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, et al. NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(4):216\u201325. https:\/\/doi.org\/10.6004\/jnccn.2024.0024.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"9860_CR48","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","volume":"22","author":"RJ Motzer","year":"2024","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al. NCCN Guidelines\u00ae Insights: Kidney Cancer, Version 2.2024. J Natl Compr Canc Netw. 2024;22(1):4\u201316. https:\/\/doi.org\/10.6004\/jnccn.2024.0008.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"9860_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al. NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(3):140\u201350. https:\/\/doi.org\/10.6004\/jnccn.2024.0019.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"9860_CR50","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/14712598.2021.1929168","volume":"21","author":"JL Wong","year":"2021","unstructured":"Wong JL, Rosenberg JE. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma. Expert Opin Biol Ther. 2021;21(7):863\u201373. https:\/\/doi.org\/10.1080\/14712598.2021.1929168.","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"9860_CR51","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"key":"9860_CR52","doi-asserted-by":"publisher","unstructured":"Kobayashi M, Numakura K, Hatakeyama S, Muto Y, Sekine Y, Sasagawa H, et al. Severe immune-related adverse events in patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 polymorphism. Genes (Basel). 2022;13(7). https:\/\/doi.org\/10.3390\/genes13071204.","DOI":"10.3390\/genes13071204"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09860-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09860-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:02:33Z","timestamp":1792083753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09860-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9860"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09860-5","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"126"}}